We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event (Photo courtesy of LumiraDx)
Image: LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event (Photo courtesy of LumiraDx)
LumiraDx (London, UK) attended the virtual event of this year’s Medlab Middle East, the leading medical laboratory exhibition in the region for over 20 years. The event brought together over 23,000 medical laboratory, healthcare and trade professionals from more than 140 countries.

In 2021 Medlab Middle East was run as a hybrid event and once again co-locating with Arab Health, bringing together the healthcare and laboratory communities. This year’s online event allowed delegates to network with industry peers, meet virtually, explore the latest products and attend educational sessions. LumiraDx exhibited online for the first time at Medlab Middle East and introduced its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions at MEDLAB Middle East 2021, including its recently launched SARS-CoV-2 Antigen Test for use on the LumiraDx Platform which delivers results in 12 minutes with 97.6% PPA to an EUA approved RT-PCR method within the first 12 days of symptom onset. The use of a LumiraDx SARS-CoV-2 Ag Test on the LumiraDx Instrument enables the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Also on display was the LumiraDx SARS-CoV-2 Ag Pool Test, a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to five individuals suspected of COVID-19 or up to five asymptomatic individuals. Used with the LumiraDx Platform, the test offers a rapid, scalable and cost-effective screening solution for infectious individuals. The company also showcased the LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform, the test delivers rapid results at the point of care.

Related Links:
LumiraDx

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
Human Chorionic Gonadotropin (hCG) Test
OSOM hCG Combo Test
New
Platinum Supplier
Hormonal Test
Endocrine Array
New
High-Throughput Cellular Screening System
FLIPR Penta

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.